ADHD :: FDA approval of Vyvanse as a novel treatment for ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

NHS :: Should the NHS curb spending on translation services?

In December it was reported that the NHS was spending ?55 million (?82m; $107m) each year on translation services. In this week?s BMJ, two doctors practising in inner London go head to head over whether language services in the NHS should be curbed.

HIV :: Researchers discover new details about HIV-1 entry and infection

The primary targets of HIV-1 infection in the human vagina have been definitively identified in a new study published in the February 2007 issue of the journal Immunity, published by Cell Press. The findings are likely to guide development of new strategies that will prevent HIV-1 transmission.

Stomach Cancer :: Family size influences the stomach cancer risk

Being a member of a large family may not be best for your health. A new study found that family size greatly influenced the development of stomach cancer linked to the bacterium Helicobacter pylori, and younger siblings from large families appeared to be especially vulnerable to the most common type of stomach cancer.

Medicare :: Major variation in Medicare Rx drug costs

As Congress debates changes to the Medicare Part D prescription drug plans, a new study finds tremendous variation in what seniors in different states pay for the same medications, even if they choose the lowest-cost Part D plans in their areas. The highest costs often occur in the lowest-income, lowest cost-of-living areas.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack